利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.024 秒)

    HGF-SF monoclonal antibody combinations
    7.
    发明授权
    HGF-SF monoclonal antibody combinations 有权
    HGF-SF单克隆抗体组合

    公开(公告)号：US07459536B1

    公开(公告)日：2008-12-02

    申请号：US10129596

    申请日：2000-11-09

    申请人： Boliang Cao ,  George Vande Woude

    发明人： Boliang Cao ,  George Vande Woude

    IPC分类号： C07K16/00

    CPC分类号： C07K16/22 ,  A61K2039/505

    摘要： The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF/SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer.

    摘要翻译： 本发明提供特异性结合HGF / SF并抑制HGF / SF活性的抗HGF / SF抗体的组合。 本发明还提供了包含三种或更多种抗HGF / SF抗体的抗HGF / SF抗体的组合，所述抗HGF / SF抗体选自由杂交瘤1C10-F1-A11产生的抗体＃1，由杂交瘤8H2- 由杂交瘤13B1-E4-E10产生的F2-B10，抗体＃5，由杂交瘤15D7-B2产生的抗体＃7和由杂交瘤31D4-C9-D4产生的抗体＃10。 本发明还提供了一种治疗受试者的癌症的方法，包括向受试者施用抗HGF / SF抗体的组合，由此抗体与肝细胞生长因子结合，由此抗体与肝细胞生长因子的结合导致 抑制肝细胞生长因子结合肝细胞生长因子受体，从而抑制肝细胞生长因子结合受体导致癌症生长的抑制，从而治疗癌症。

    HGF-SF MONOCLONAL ANTIBODY COMBINATIONS
    8.
    发明申请
    HGF-SF MONOCLONAL ANTIBODY COMBINATIONS 审中-公开
    HGF-SF单克隆抗体组合

    公开(公告)号：US20090155284A1

    公开(公告)日：2009-06-18

    申请号：US12326602

    申请日：2008-12-02

    申请人： BOLIANG CAO ,  George Vande Woude

    发明人： BOLIANG CAO ,  George Vande Woude

    IPC分类号： A61K39/395 ,  C07K16/18 ,  G01N33/53 ,  G01N33/574

    CPC分类号： C07K16/22 ,  A61K2039/505

    摘要： The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF/SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer.

    摘要翻译： 本发明提供特异性结合HGF / SF并抑制HGF / SF活性的抗HGF / SF抗体的组合。 本发明还提供包含三种或更多种抗HGF / SF抗体的抗HGF / SF抗体的组合，所述抗HGF / SF抗体选自：由杂交瘤1C10-F1-A11产生的抗体＃1，由杂交瘤8H2产生的抗体＃4 由杂交瘤13B1-E4-E10产生的-F2-B10抗体＃5，由杂交瘤15D7-B2产生的抗体＃7和由杂交瘤31D4-C9-D4产生的抗体＃10。 本发明还提供了一种治疗受试者的癌症的方法，包括向受试者施用抗HGF / SF抗体的组合，由此抗体与肝细胞生长因子结合，由此抗体与肝细胞生长因子的结合导致 抑制肝细胞生长因子结合肝细胞生长因子受体，从而抑制肝细胞生长因子结合受体导致癌症生长的抑制，从而治疗癌症。

    Geldanamycin and Derivatives Inhibit Cancer Invasion and Identify Novel Targets
    9.
    发明申请
    Geldanamycin and Derivatives Inhibit Cancer Invasion and Identify Novel Targets 审中-公开
    格尔德霉素和衍生物抑制癌症入侵和鉴定新靶标

    公开(公告)号：US20070297980A1

    公开(公告)日：2007-12-27

    申请号：US10594136

    申请日：2005-03-28

    申请人： Qian Xie ,  David Wenkert ,  Yuchai Shen ,  George Vande Woude ,  Ricky Hay

    发明人： Qian Xie ,  David Wenkert ,  Yuchai Shen ,  George Vande Woude ,  Ricky Hay

    IPC分类号： A61K31/395 ,  A61K31/397 ,  A61K51/04 ,  A61P35/00 ,  A61P35/04 ,  C07D225/06

    CPC分类号： C07D225/06

    摘要： Geldanamycin derivatives that block the uPA-plasmin network and inhibit growth and invasion by glioblastoma cells and other tumors at femtomolar concentrations are potentially highly active anti-cancer drugs. GA and various 17-amino-17-demethoxygelddanamycin derivatives are disclosed that block HGF/SF-mediated Met tyrosine kinase receptor-dependent uPA activation at fM levels. Other ansamycins (macbecins I and II), GA derivatives, and radicicol required concentrations several logs higher (≧nM) to achieve such inhibition. The inhibitory activity of tested compounds was discordant with the known ability of drugs of this class to bind to hsp90, indicating the existence of a novel target(s) for HGF/SF-mediated events in tumor development. Methods of using such compounds to inhibit cancer cell activities and to treat tumors are disclosed. Such treatment with low doses of these highly active compounds provide an option for treating various Met-expressing tumors, in particular invasive brain cancers, either alone or in combination with conventional surgery, chemotherapy, or radiotherapy.

    摘要翻译： 阻断uPA-纤溶酶网络并抑制成胶质细胞瘤细胞和其他肿瘤在飞生物浓度下的生长和侵袭的格尔德霉素衍生物是潜在的高活性抗癌药物。 GA和各种17-氨基-17-脱甲氧基格丹丹霉素衍生物被公开，以fM水平阻断HGF / SF介导的Met酪氨酸激酶受体依赖性uPA活化。 其他ansamycins（macbecins I和II），GA衍生物和radicicol要求的浓度几个日志更高（> = nM）达到这种抑制。 测试化合物的抑制活性与本类药物已知的与hsp90结合的能力不一致，表明在肿瘤发展中存在HGF / SF介导的事件的新靶标。 公开了使用这些化合物抑制癌细胞活性和治疗肿瘤的方法。 用低剂量的这些高活性化合物的这种治疗提供了单独或与常规手术，化学疗法或放射疗法组合治疗各种Met表达肿瘤，特别是侵袭性脑癌的选择。